Supported by:  Ipsen 
In primary biliary cholangitis, it is important to look beyond the liver to make meaningful improvements for patients, so how can we optimize regular disease monitoring alongside the impact of symptoms on patients’ lives? Join us to

Supported by: Novo Nordisk
Join us as we review the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH, non-alcoholic steatohepatitis), including the impact of underlying metabolic comorbidities. We will als

Supported by:  Perspectum
In this session we will introduce cT1, a well-established biomarker in liver disease derived from MRI technology. cT1 has played a pivotal role in numerous clinical trials focused on Steatotic Liver Disease, proving its effectiv

Supported by: Genentech, A Member of the Roche Group
This program will provide an overview of HCC disease and staging, IMbrave150 including the clinical trial design, patient characteristics, pivotal efficacy and safety data, and exploratory subgroup ana

Supported by: Albireo Pharma, Inc., an Ipsen Company
This presentation will focus on two rare, genetic cholestatic liver diseases: Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Drs. Mohammad (Vanderbilt University) an

Supported by: Madrigal Pharmaceuticals
This session will explore several emerging concepts in NASH including: (1) epidemiology and comorbidities, (2) pathophysiology and the role of lipotoxicity in the liver, (3) morbidity and mortality, (4) patient iden

Supported by: Becton, Dickinson and Company 
This symposium will explore the interdisciplinary relationship between Hepatology and Interventional Radiology in treating patients with non-malignant ascites.  Dr. Michael Charlton and Dr. George Behrens will

Supported by: FUJIFILM Healthcare Americas Corporation
CC surveillance is associated with reduced HCC mortality. However, ultrasound has insufficient sensitivity for early tumor detection, prompting increasing interest in blood-based biomarkers. In this

Supported by: E-Scopics
Come “See” how Hepatoscope two-dimensional ultrasound tools can shift the paradigm of early detection and monitoring of MASLD-MASH. With Hepatoscope, E-Scopics brings LSM and a complete quantification suite of Ultrasound Imaging i